Jena Valve Technology
Medical Devices, 4 Cromwell, Irvine, California, 92610, United States, 51-200 Employees
Phone Number: 19*********
Who is JENAVALVE TECHNOLOGY
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR)...
Read More
-
Headquarters: 4 Cromwell, Irvine, California, 92610, United States
-
Date Founded: 2013
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
John Kilcoyne
Email
Phone
Industry: Medical Devices
SIC Code: 3841
|
NAICS Code: 339112 |
Show More
Does something look wrong? Fix it. | View contact records from JENAVALVE TECHNOLOGY
JenaValve Technology Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding JenaValve Technology
Answer: JenaValve Technology's headquarters are located at 4 Cromwell, Irvine, California, 92610, United States
Answer: JenaValve Technology's phone number is 19*********
Answer: JenaValve Technology's official website is https://jenavalve.com
Answer: JenaValve Technology's revenue is $10 Million to $25 Million
Answer: JenaValve Technology's SIC: 3841
Answer: JenaValve Technology's NAICS: 339112
Answer: JenaValve Technology has 51-200 employees
Answer: JenaValve Technology is in Medical Devices
Answer: JenaValve Technology contact info: Phone number: 19********* Website: https://jenavalve.com
Answer: JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month